Food label management measures for advice on production and shelf life text height shall not be less than 3 mm.
Time of Update: 2020-08-20
like this food, the obvious position is only marked shelf life, but the production date has to look for half a day to find in the corner of the blue area, and blurred.
A patient's death occurs! Clinical trials for generic CAR-T treatment sympons for MM have been halted by the FDA.
Time of Update: 2020-08-10
to the death of a patient with recurrent or refractive multiple myeloma (MM) treatment. the patient, who had previously received multiple treatments and failed treatment, died of treatment-related cardiac arrest after receiving a level 2 dose (DL2
Take stock of domestic and foreign guides to see how to deal with the first relapse MM!
Time of Update: 2020-07-18
Introduction For the first recurrent multiple myeloma, how to choose a treatment plan? Learn about the protocol recommendations of Isazomi containing second-generation oral protease inhibitors (PIs) by taking stock of domestic and foreign guidelines
Results of darzale clinical study significantly prolonged PFS in MM patients
Time of Update: 2020-06-19
The results showed that in the newly diagnosed MM patients who met the conditions of ASCT, compared with the standard therapy of bortezomib + thalidomide + dexamethasone (VTD), adding darzalex to VTD before and after transplantation improved
FDA approves update of prescription label information for ammo MM-targeted drug Kyprolis (carzofilmib)
Time of Update: 2020-06-11
recently, Amgen announced that the U.S. Food and Drug ( FDA ( FDA) has approved the multiple myeloma (MM) targeted drug Kyprolis (carfilzomib) prescription label information update, including phase III clinical
GSK publishes full results from elantamab mafodotin (GSK2857916) treatment OfR/R MM critical clinical study
Time of Update: 2020-06-06
GlaxoSmithKline (GSK), the UK Pharmaceutical ( , recently announced that it has published an assessment of B-cell mature antigen (BCMA) targeted antibodies drug (http
ORR up to 78%! Selinexor multiple combination therapies are bright in MM clinical
Time of Update: 2020-06-02
Selinexor is a pioneering, oral, selective nuclear output inhibitor (SINE) compound that binds and inhibits the functioning of the nucleo-output protein XPO1 (also known as CRM1), causing tumor suppressors to accumulate in the nucleus, which
New discovery of MM treatment: Aiming at cd229, use car-t to clear cancer cells!
Time of Update: 2020-02-11
At the meeting, Bluebird biology also released the clinical data of bb21217 for MM treatment, which is also a car-t cell therapy targeted at BCMA.
Amgen bite immunotherapy combined with Revlimid can prevent mm recurrence
Time of Update: 2019-12-14
At last year's annual meeting of the American Society of Hematology (ash), Amgen's anti BCMA T-cell binding agent achieved a response rate of 70% in early clinical trials
Mm classic drug: lainadu amine is the best in the world
Time of Update: 2019-07-22
On 5th of this month, nmpa approved the import registration application of daratumab injection, a Johnson & Johnson heavyweight product, for the single drug treatment of relapsed
Janssen Pharmaceutical publishes the phase III clinical research data of darzalex (daratumumab) in MM patients
Time of Update: 2019-07-15
Recently, Johnson & Johnson's Janssen Pharmaceutical (http://www.chemdrug.com/) Company (http://www.chemdrug.com/company/) published the data of phase III clinical study Columba
States to treat multiple refractory multiple myeloma (mm)
Time of Update: 2019-07-09
July 9, 2019 / BIOON / - karyopharm therapeutics is an oncology centered pharmaceutical company that focuses on the discovery and development of innovative therapies for nuclear
6 mm diameter magnetic drug delivery device
Time of Update: 2017-02-26
Researchers at the University of British Columbia, Canada, have successfully developed a magnetic drug delivery implant with a diameter of only 6 mm, using silicon sponge
Merrimack company mm-398, an authorized partner of Taiwan smart engine biotechnology, has obtained the FDA's new drug priority review qualification
Time of Update: 2015-06-25
announced on June 25 that Merrimack pharmaceutical company, the authorized partner of the company, was informed by the US Food and Drug Administration
Baxter has invested heavily in mm-398, a new pancreatic cancer drug
Time of Update: 2014-09-25
Source: great wisdom astak news agency announced on Wednesday that the company will invest to buy Merrimack pharmaceutical's new pancreatic cancer drug mm-398
FDA approved Velcade for multiple myeloma (mm) retreatment
Time of Update: 2014-08-11
FDA approved Velcade's Supplemental new drug application (SNDA) for retreatment, including a phase II study and other supporting data.